Form 4: OnKure Therapeutics CFO Sells Shares to Cover Tax Obligations

Jason A. Leverone, CFO of OnKure Therapeutics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 4, 2025, Jason A. Leverone, the Chief Financial Officer of OnKure Therapeutics, sold 1,278 shares of Class A Common Stock at a weighted average price of $3.3276.
• The sales were executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) under the company's 2023 RSU Equity Incentive Plan.
• Following the transaction on April 4, Leverone beneficially owned 15,053 shares.
• On April 7, 2025, Leverone sold 1,844 shares of Class A Common Stock at a weighted average price of $2.671.
• Following the transaction on April 7, Leverone beneficially owned 13,209 shares.
• The price per share for the April 4 transaction ranged from $3.10 to $3.58, and for the April 7 transaction, it ranged from $2.57 to $3.03.

Sentiment

Score: 5

Explanation: This is a routine transaction (Form 4 filing) related to tax obligations, so the sentiment is neutral.

Industry Context

Sales of shares by company executives are a common occurrence, often related to compensation or personal financial planning. It's typical for executives to sell shares to cover tax obligations when RSUs vest.

Stakeholder Impact

• The sale of shares by the CFO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect on shareholders.

Key Dates

Keywords

Form 4, OnKure Therapeutics, Jason A. Leverone, CFO, Class A Common Stock, Share Sale, RSU, Tax Withholding